Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acer MedicalROCO:6857 56 Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus rates ROCO:6857 with a GF Score™ of 56/100 and a GF Value™ of NT$218.25 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 479 Healthcare Providers & Services companies, Acer Medical ranks worse than 208768.06% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Acer Medical's Debt-to-EBITDA or its related term are showing as below:
ROCO:6857'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.12 Med: -0.02 Max: 0
Current: -0.12
ROCO:6857's Debt-to-EBITDA is ranked worse than 100% of 479
companies
in the Healthcare Providers & Services industry
Industry Median: 2.18
vs ROCO:6857: -0.12
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Acer Medical Debt-to-EBITDA Related Terms
Acer Medical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Acer Medical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6857 vs VEEV, BTSG, TEM: Debt-to-EBITDA Comparison
For the Health Information Services subindustry, Acer Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acer Medical Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Acer Medical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Acer Medical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2026) EBITDA data.
Acer Medical (ROCO:6857) has a Debt-to-EBITDA of 0.00 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Acer Medical. According to the industry distribution chart, Acer Medical ranks #999999 out of 479 companies in the Healthcare Providers & Services industry.
Is Acer Medical's Debt-to-EBITDA too high?
Acer Medical's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Acer Medical ranks #999999 out of 479 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Acer Medical has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Acer Medical's Debt-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Acer Medical ranks #999999 out of 479 companies for Debt-to-EBITDA. This places Acer Medical in the lower half of its industry. The industry median Debt-to-EBITDA is 2.18. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.18, based on 479 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Acer Medical. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acer Medical's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acer Medical stock overvalued right now?
Based on GuruFocus' analysis, Acer Medical (ROCO:6857) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$218.25, compared to a current price of NT$90.00 — trading 58.8% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Acer Medical's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Acer Medical (ROCO:6857), the current Debt-to-EBITDA is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acer Medical (ROCO:6857) Overvalued in 2026?
Based on GuruFocus' analysis, Acer Medical stock appears to be undervalued.
The current stock price of NT$90.00 is trading 58.8% below its estimated GF Value™ of NT$218.25.
GuruFocus considers Acer Medical to be Significantly Undervalued.
Key valuation signals for ROCO:6857:
Debt-to-EBITDA: 0.00
GF Value™: NT$218.25 vs. price of NT$90.00 (58.8% below fair value)
No single metric tells the full story. See the ROCO:6857 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acer Medical Inc focuses on improving human health and well-being through artificial intelligence. It focuses on applying artificial intelligence and large data to the area of healthcare. Acer Medical is capable of designing, developing, commercializing, as well as implementing AI solutions in medical institutions.
56GF Score
Get the complete analysis for ROCO:6857
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6857 has been successfully added to your 
